Braintree, Massachusetts–based Microbot develops the Liberty single-use endovascular robotic surgical system. It designed Liberty for use in neurovascular, cardiovascular and peripheral vascular procedures. The system includes a compact design and remote operating capabilities to reduce radiation exposure and physical strain on physicians.
Microbot Medical believes Liberty’s remote operation could potentially make it the first system to democratize endovascular interventional procedures.
The agreement with Medimor governs the manufacturing of Liberty for its first-in-human clinical trial. It also covers the initial Liberty systems expected to hit the market following the completion of regulatory requirements. Medimor provides new product introduction (NPI) solutions and full turnkey manufacturing for medical devices. It serves as a one-stop shop for contract manufacturing, including integration, parts cleaning, clean room assembly and testing.
“We continue our transition from a research and development stage to a clinical and commercial stage in the field of endovascular robotics,” said Simon Sharon, Microbot Medical CTO and GM. “We believe that the manufacturing agreement supports our efforts to deliver a state-of-the-art advanced robotic system and facilitates our next steps.”
